Multidrug resistance: can new drugs help chemotherapy score against cancer?

There is much debate as to whether P-gp appears on NSCLC tumors frequently enough to provide statistically meaningful trial results. Arguing that the benefits of P-gp inhibitors are limited to tumors expressing P-gp, some authorities propose studies that enroll only patients whose tumors are already...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2003-02, Vol.95 (4), p.255-257
1. Verfasser:	Goldman, Bruce
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical Trials, Phase III as Topic Cyclosporins - pharmacology Dibenzocycloheptenes - pharmacology Drug resistance Drug Resistance, Multiple Drug Resistance, Neoplasm Drugs, Investigational - pharmacology Gene Expression Regulation, Neoplastic Humans Leukemia, Myeloid, Acute - drug therapy Lung Neoplasms - drug therapy Membrane Transport Proteins Multidrug Resistance-Associated Proteins - drug effects Multidrug Resistance-Associated Proteins - metabolism National Institutes of Health (U.S.) Neoplasms - drug therapy Neoplasms - metabolism Piperidines - pharmacology Pyridines - pharmacology Quinolines - pharmacology United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is much debate as to whether P-gp appears on NSCLC tumors frequently enough to provide statistically meaningful trial results. Arguing that the benefits of P-gp inhibitors are limited to tumors expressing P-gp, some authorities propose studies that enroll only patients whose tumors are already P-gp-positive.
ISSN:	0027-8874 1460-2105
DOI:	10.1093/jnci/95.4.255